Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its IRAK4 inhibitor, CA-4948, at the AACR-NCI-EORTC Virtual Conference. The data demonstrates CA-4948's potential in treating non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndromes. Notably, the research indicates CA-4948 may synergize with existing therapies and effectively cross the blood-brain barrier, enhancing survival rates in aggressive CNS lymphoma. This supports ongoing Phase 1 clinical trials aimed at examining its effectiveness in various hematologic cancers.
Curis, Inc. (NASDAQ: CRIS) announced on October 1, 2021, that its Compensation Committee approved inducement stock options for five new employees, totaling 106,350 shares. Each option has a 10-year term and an exercise price set at the closing stock price on the grant date. Vested options will occur over four years, beginning with 25% vesting after the first year of employment. These grants are part of Curis's strategy to attract talent as it continues to develop innovative cancer therapies, including various ongoing clinical trials for its product candidates.
Curis, a biotechnology company focused on cancer therapeutics, announced the participation of CEO James Dentzer in two upcoming virtual healthcare conferences. The Morgan Stanley Virtual Global Healthcare Conference is set for September 10, 2021, at 11:00 a.m. ET, followed by the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20 a.m. ET. Presentations will be available via live webcast and later as a replay on Curis' investor website. Curis is developing key cancer drugs, including CA-4948, which is in clinical trials for non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) reported its Q2 2021 financial results, showing a net loss of $10.8 million ($0.12/share), compared to a loss of $6.7 million in Q2 2020. Revenues slightly decreased to $2.3 million, primarily from royalties. The company continues to advance its pipeline, notably the IRAK4 inhibitor CA-4948, demonstrating positive data in clinical trials for AML/MDS patients. Operating expenses rose to $12.9 million due to increased R&D costs. Curis holds $160.7 million in cash, sufficient to fund operations into 2024.
Curis, Inc. (NASDAQ: CRIS) announced it will release its second quarter 2021 financial results on August 3, 2021, after US market close. A conference call will be held at 4:30 pm ET the same day. The company is focused on developing innovative therapeutics for cancer treatment, including collaborations on several clinical trials. Notably, CA-4948 is currently in Phase 1/2 trials for non-Hodgkin lymphoma and has received Orphan Drug Designation for acute myeloid leukemia from the FDA.
Curis, Inc. (NASDAQ: CRIS) announced on July 1, 2021, the approval of inducement stock options for 259,550 shares to fifteen new employees. These stock options have an exercise price equal to the closing price on the grant date, vesting over four years. Curis develops cancer therapeutics, including collaborations on various treatments such as the IRAK4 inhibitor CA-4948, currently in clinical trials. This grant is intended to incentivize new hires and enhance employee retention.
Curis, Inc. (NASDAQ: CRIS) will be added to the Russell 2000®, 3000®, and Microcap® indexes, effective June 28, 2021. This inclusion recognizes Curis's market capitalization among the largest U.S. stocks, enhancing its visibility within the investment community. The Russell indexes serve as benchmarks for approximately $10.6 trillion in assets, indicating Curis's increased accessibility to institutional investors. CEO James Dentzer expressed enthusiasm for this milestone, highlighting the importance of index membership for overall growth and investor relations.
Curis, Inc. (NASDAQ: CRIS) announced positive updates from its Phase 1/2 trial of CA-4948, an IRAK4 kinase inhibitor, at the EHA 2021 Congress. The trial targets patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings show effective dose at 300 mg BID, with significant hematologic recovery and objective responses in patients with spliceosome or FLT3 mutations. CA-4948 also demonstrated synergistic activity in preclinical studies when combined with azacitidine and venetoclax. The company plans to initiate combination studies later this year.
Curis (NASDAQ: CRIS) announced a virtual KOL event on June 11, 2021, to discuss progress on CA-4948, a first-in-class IRAK4 kinase inhibitor. The event will include updated data from the Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), initially presented at the European Hematology Association 2021 Virtual Congress. Curis CEO James Dentzer and Dr. Guillermo Garcia-Manero from MD Anderson Cancer Center will lead the discussion, with a Q&A session to follow. A live webcast will be available on Curis' website.
Curis, Inc. (NASDAQ: CRIS) announced a virtual symposium titled "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond", occurring on June 18, 2021. The event will feature discussions on the emerging checkpoint molecule VISTA, its implications in various diseases, and ongoing development programs, including Curis's anti-VISTA antibody, CI-8993, currently in clinical trials. Notable speakers include Dr. Randolph Noelle and Dr. Padmanee Sharma. Attendees will explore topics such as checkpoint therapy, VISTA's role in the tumor microenvironment, and advances in clinical development.